By Counterforce Health Team in Evkeeza (evinacumab-dgnb) —

How to Get Evkeeza (Evinacumab) Covered by Blue Cross Blue Shield in Virginia: Complete PA Guide and Appeals Process

Answer Box: Getting Evkeeza Covered by Blue Cross Blue Shield in Virginia

Evkeeza (evinacumab) requires prior authorization from all Blue Cross Blue Shield plans in Virginia. For fastest approval: (1) Confirm HoFH diagnosis with genetic testing or clinical criteria, (2) Document maximum tolerated lipid-lowering therapy (statin + ezetimibe + PCSK9 inhibitor), and (3) Submit PA request through your BCBS provider portal with specialist prescription. If denied, Virginia's State Corporation Commission Bureau of Insurance offers external review within 120 days. Start with your prescriber today to gather required documentation.

Table of Contents

Plan Types & Coverage Implications

Blue Cross Blue Shield in Virginia operates through multiple independent licensees, with Anthem Blue Cross and Blue Shield covering the largest market share at approximately 43%. Other BCBS affiliates like CareFirst BlueCross BlueShield serve specific regions.

Key plan distinctions for Evkeeza coverage:

  • HMO/POS Plans: Require referrals to specialists; your primary care physician must refer you to a cardiologist or lipidologist for Evkeeza evaluation
  • PPO/EPO Plans: Allow direct specialist access; you can schedule with a lipid specialist without referral
  • Medicare Advantage: May have different formulary tiers and PA criteria than commercial plans
  • Medicaid Plans: Coverage varies significantly; Virginia Medicaid expanded in 2019, improving access to specialty medications
Note: Always verify your specific plan's network and formulary through your member portal, as requirements can vary even within the same insurer.

Formulary Status & Tier Placement

Evkeeza typically appears on specialty drug tiers (Tier 4 or 5) across BCBS plans due to its high cost—approximately $450,000 annually for a 75kg adult. Most BCBS Virginia plans classify Evkeeza as:

  • Non-preferred specialty medication requiring prior authorization
  • Step therapy required before approval
  • Quantity limits applied (typically 2 vials per 28 days)
  • Site of care restrictions favoring home infusion or physician offices over hospital outpatient

Alternative agents your plan may prefer first include:

  • PCSK9 inhibitors (evolocumab/Repatha, alirocumab/Praluent)
  • Ezetimibe combined with maximum statin therapy
  • LDL apheresis for severe cases

Prior Authorization Requirements

All BCBS Virginia plans require prior authorization for Evkeeza. The PA process typically involves:

Required Documentation

  • HoFH diagnosis confirmation via genetic testing or clinical criteria
  • Age verification (≥5 years old per FDA labeling)
  • Specialist prescription from cardiologist, lipidologist, or endocrinologist
  • Laboratory results showing LDL-C levels ≥100 mg/dL despite maximum therapy
  • Treatment history documenting trials and failures of required therapies

Genetic Testing Requirements

BCBS typically requires prior authorization for HoFH genetic testing through Carelon Medical Benefits Management. Submit requests via:

  • Online portal for fastest processing
  • Phone: 1-866-745-1783 (Mon-Fri, 8 AM–6 PM)
  • Include family history, clinical presentation, and planned genetic tests (LDLR, APOB, PCSK9 mutations)

Step Therapy & Medical Necessity

Step therapy requirements are strict for Evkeeza approval. Patients must demonstrate:

Maximally Tolerated Lipid-Lowering Therapy

  1. High-intensity statin at maximum tolerated dose (unless contraindicated)
  2. Ezetimibe 10 mg daily
  3. PCSK9 inhibitor (evolocumab or alirocumab) at full dose

Exceptions to PCSK9 requirement:

  • Both agents contraindicated or not tolerated (documented)
  • Patient has two LDL-receptor negative mutations (genetic proof required)

Medical Necessity Criteria

  • LDL-C remains ≥70 mg/dL despite maximum therapy
  • Adherence documented to all prescribed agents
  • Contraindications clearly noted for any skipped therapies
  • Treatment goals established by lipid specialist
Tip: Document specific reasons for therapy failures (muscle pain with statins, GI intolerance with ezetimibe) rather than general "patient intolerance" statements.

Specialty Pharmacy Network

Evkeeza must be obtained through BCBS-approved specialty pharmacies and administered at preferred sites:

Preferred Infusion Sites

  • Home infusion (most cost-effective)
  • Physician's office
  • Independent infusion centers (non-hospital)

Restricted Sites

Hospital outpatient infusion requires additional justification:

  • First Evkeeza infusion only
  • Re-initiation after ≥6 months off therapy
  • Special monitoring needs not available elsewhere

Infusion Process

  • Dosing: 15 mg/kg IV over 60 minutes every 4 weeks
  • Monitoring: Vital signs, infusion reactions, periodic lab work
  • Coordination: Specialty pharmacy coordinates with infusion site

Cost-Share Basics

Educational overview of typical cost-sharing structures (not financial advice):

  • Specialty tier copays: Often $100-500+ per infusion
  • Coinsurance: May apply 20-40% after deductible
  • Deductible: High-deductible plans require meeting deductible first
  • Out-of-pocket maximum: Provides annual spending cap

Potential cost assistance:

  • Regeneron's myRARE program: May offer copay support for eligible patients
  • Foundation grants: Organizations like Patient Access Network Foundation
  • State programs: Virginia may have additional assistance programs

Submission Process

BCBS Provider Portal Submission

  1. Log into provider portal specific to your BCBS plan
  2. Complete PA request form with all required fields
  3. Upload supporting documents:
    • Genetic test results or clinical HoFH criteria
    • Lab values (LDL-C, lipid panel)
    • Treatment history and failure documentation
    • Specialist consultation notes
  4. Submit before first infusion to avoid claim denials

Required Forms by Plan

  • Anthem BCBS: Check provider portal for current PA forms
  • CareFirst: May use different submission process
  • Medicare Advantage: Often requires additional CMS-specific documentation
Note: Verify current submission requirements with your specific BCBS plan, as processes may vary by region and employer group.

Common Approval Patterns

Successful PA submissions typically include:

Strong Clinical Documentation

  • Definitive HoFH diagnosis with genetic confirmation when possible
  • Quantified LDL-C levels before and during prior therapies
  • Detailed treatment timeline showing adequate trials and specific reasons for discontinuation
  • Specialist attestation of medical necessity

Complete Prior Therapy Documentation

  • Statin trials: Specific agents, doses, duration, and reasons for discontinuation
  • Ezetimibe response: LDL-C reduction achieved and current status
  • PCSK9 inhibitor outcomes: Both evolocumab and alirocumab if tried

Regulatory Alignment

  • FDA labeling compliance: Age requirements, indication specificity
  • Guideline references: Cite relevant lipid management guidelines
  • Safety monitoring plan: Infusion reaction protocols, ongoing lab monitoring

Virginia Appeals Process

If your Evkeeza PA is denied, Virginia offers robust appeal rights through the State Corporation Commission Bureau of Insurance.

Internal Appeals First

  • Timeline: Complete insurer's internal appeal process first
  • Deadline: Varies by plan, typically 60-180 days from denial
  • Documentation: Submit additional clinical evidence not in original PA

External Review Process

Eligibility

  • Denial reasons: Medical necessity or experimental/investigational status only
  • Timeline: Must request within 120 days of final denial
  • Plans covered: Virginia-issued plans and opted-in self-funded plans

Required Forms

  • Form 216-A: Main external review request
  • Form 216-B: If someone else is filing for you
  • Form 216-D: For experimental/investigational denials only

Submission Details

  • Address: State Corporation Commission, Bureau of Insurance – External Review, P.O. Box 1157, Richmond, VA 23218
  • Fax: (804) 371-9915
  • Email: [email protected]
  • Phone: 1-877-310-6560

Timeline

  • Standard review: Decision within 45 days, total process ≤60 days
  • Expedited review: 72 hours for life/health threatening situations (requires Form 216-C physician certification)
From our advocates: We've seen patients succeed in Virginia external review by including updated clinical evidence not submitted during internal appeals. One common winning strategy involves providing more recent LDL-C levels showing continued elevation despite maximum therapy, along with specialist letters emphasizing the unique mechanism of Evkeeza for HoFH patients who don't respond adequately to PCSK9 inhibitors.

Virginia Resources

  • Managed Care Ombudsman: Additional support for HMO/managed care plan issues
  • Virginia Poverty Law Center: Legal assistance for complex cases
  • Consumer Services: 1-877-310-6560 for guidance before filing

When to Contact Counterforce Health

Navigating complex prior authorization requirements for specialty medications like Evkeeza can be overwhelming. Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. Their platform ingests denial letters, plan policies, and clinical notes to identify specific denial reasons and draft point-by-point rebuttals aligned to your plan's requirements.

For Evkeeza appeals, Counterforce Health can help identify whether denials stem from insufficient HoFH documentation, inadequate prior therapy trials, or procedural issues, then provide the right evidence citations from FDA labeling, specialty guidelines, and peer-reviewed studies to strengthen your case.

FAQ

How long does BCBS PA take in Virginia? Most BCBS plans provide PA decisions within 5-10 business days for standard requests. Expedited reviews (when medically urgent) typically take 24-72 hours.

What if Evkeeza is non-formulary on my plan? Request a formulary exception through your BCBS plan's pharmacy department. Include medical necessity documentation and specialist support for why preferred alternatives are inadequate.

Can I get expedited review if my LDL-C is extremely high? Yes, if your physician certifies that delay could jeopardize your health. Use Form 216-C for Virginia external review or contact your BCBS plan for internal expedited appeals.

Does step therapy apply if I failed these medications outside Virginia? Yes, documented treatment failures from other states typically satisfy BCBS step therapy requirements. Ensure you have complete medical records from prior providers.

What counts as "maximum tolerated" statin therapy? The highest dose you can take without unacceptable side effects, documented by your physician. This might be a lower dose if you experience muscle pain, liver enzyme elevation, or other adverse effects.

How do I find BCBS-approved infusion sites in Virginia? Contact your BCBS member services or check your plan's provider directory for "infusion services" or "home health." Your specialty pharmacy can also help coordinate approved sites.

What if my employer plan is self-funded? Self-funded plans may opt into Virginia's external review process. If not, you may have federal external review rights through HHS. The Bureau of Insurance can help determine your options.

Can I appeal directly to Virginia if BCBS delays my internal appeal? Virginia law allows external review if the insurer fails to complete internal appeals within required timeframes. Contact the Bureau of Insurance for guidance on your specific situation.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and change frequently. Always verify current requirements with your specific BCBS plan and consult healthcare providers for medical decisions. For personalized assistance with complex appeals, consider consulting Counterforce Health or other qualified advocacy services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.